Analysis of probable predictors of aggressive multiple sclerosis
https://doi.org/10.20538/1682-0363-2019-4-127-135
Abstract
Objective: to study the probable laboratory predictors of aggressive multiple sclerosis.
Materials and methods. Antibodies to myelin oligodendrocyte glycoprotein (MOG), antibodies to thyroperoxidase and markers of endothelial dysfunction in blood serum were determined in patients with multiple sclerosis (MS). These indicators were analyzed for different courses of the demyelinating process, for different severity of neurological disorders, and for various sizes of focal lesions on magnetic resonance images.
Results. In patients with aggressive multiple sclerosis, higher titers of antibodies to both myelin oligodendrocyte glycoprotein and thyroperoxidase were detected. A relationship between von Willebrand factor (vWf) and matrix metalloproteinase-9 (MMP-9) and the stage of multiple sclerosis was identified. A higher level of matrix metalloproteinase-9 was detected in MS patients with active foci of the disease on magnetic resonance images.
Conclusion. Thus, antibodies to myelin oligodendrocyte glycoprotein, antibodies to thyroperoxidase, the levels of von Willebrand factor, matrix metalloproteinase-9 and adhesion molecule sPECAM-1 can be used as laboratory predictors of the malignant course of multiple sclerosis.
About the Authors
N. N. Spirin
Yaroslavl State Medical University
Russian Federation
Russian Federation
DM, Professor, Head of Neurology Department,
5, Revolutsionnaya Str., Yaroslavl, 150000
E. V. Kiseleva
Yaroslavl State Medical University
Russian Federation
Russian Federation
PhD, Assistant, Neurology Department,
5, Revolutsionnaya Str., Yaroslavl, 150000
N. N. Spirina
Yaroslavl State Medical University
Russian Federation
Russian Federation
PhD, Assistant, Neurology Department,
5, Revolutsionnaya Str., Yaroslavl, 150000
References
1. Patsopoulos N.A., Esposito F., Reischl. J., Lehr S. et al. Genome-wide meta-analysis identifies novel multiple sclerosissusceptibility loci. Annals of Neurology. 2011; 70: 897–912. DOI: 10.1002/ana.22609.
2. Rush C.A., MacLean H.J., Freedman M.S. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nature Reviews Neurology. 2015; 11: 379–389. DOI: 10.1038/nrneurol.2015.85.
3. Boyko A.N. Selecting the best treatment for multiple sclerosis. Medical Council. 2015; (5): 78–79 (in Russ.). DOI: 10.21518/2079-701X-2015-5-7-18.
4. Teunissen C.E., Malekzadeh A., Leurs C., Bridel C., Killestein, J. Body fluid biomarkers for multiple sclerosis – the long road to clinical application. Nature Reviews Neurology. 2015; 11 (10): 585–596. DOI: 10.1038/nrneurol.2015.173.
5. Polman C.H., Reingold S.C., Edan G. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 2005. 58 (6): 840–846. DOI: 10.1002/ana.20703.
6. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann. Neurol. 2011; 69 (2): 292–302. DOI: 10.1002/ana.22366.
7. Rush C.A., MacLean H.J., Freedman M.S. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat. Rev. Neurol. 2015. 11 (7): 379–389. DOI: 10.1038/nrneurol.2015.85.
8. Spadaro M., Gerdes L.A., Krumbholz M., Ertl-Wagner B., Thaler F.S. et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016; 3 (5): 257. DOI: 10.1212/NXI.0000000000000257.
9. Lassmann H., Horssen J., Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nature Reviews. Neurology. 2012; 8: 647–656. DOI: 10.1038/nrneurol.2012.168.
10. Verigo I.I., Demko I.V., Petrova M.M., Sobko E.A., Mamaeva M.G. Von Willebrand factor and its role in endothelial dysfunction in coronary heart disease. Siberian Medical Review. 2014; 5 (89): 23–28. (in Russ.).
11. Kohriyama T., Maruyama H., Kurokawa K., Harada T., Nakamura S. Endothelial cell activation and/or injury in multiple sclerosis: analysis with von Willebrand factor and thrombomodulin. Rinsho Shinkeigaku. 1997; 37 (4): 287–291. PMID: 9248336.
12. Noubade R., Rio R., McElvany J.M.B., Zachary J.F. et al. Von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis. Am. J. Pathol. 2008; 173 (3): 892–900. DOI: 10.2353/ajpath.2008.080001.
13. Cox M.B., Bowden N.A., Scott R.J., Lechner-Scott J. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. Mult. Scler. 2013; 19 (10): 1268–1274. DOI: 10.1177/1352458513475493.
14. Fernandes K.S., Brum D.G., Palei A.C., Sandrim V.C., Guerreiro C.T. et al. Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients. J. Neuroimmunol. 2012; 249 (1–2): 56–59. DOI: 10.1016/j.jneuroim.2012.04.001.
15. Niezgoda A., Losy J. Pecam-1 expression in patients with relapsing-remitting multiple sclerosis. Folia. Morphol. (Warsz). 2002; 61 (3): 143–145. PMID: 12416929.
16. Kuenz B., Lutterotti A., Khalil M., Ehling R., Gneiss C. et al. Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis. J. Neuroimmunol. 2005; 167 (1–2): 143–149. DOI: 10,1016/j.jneuroim.2005.06.019.
17. Ioppoli C., Meucci G., Mariotti S., Martino E., Lippi A. Circulating thyroid and gastric parietal cell autoantibodies in patients with multiple sclerosis. J. Neurol. Sci. 1990; 11: 31–36. DOI: 10.1007/bf02334902.
18. Annunziata P., Lore’ F., Venturini E., Morana P., Guarino E., Borghi S. et al Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis. J. Neurol. Sci. 1999; 168 (1): 32–36. DOI: 10.1016/s0022-510x(99)00168-9.
19. Niederwieser G., Buchinger W., Bonelli R.M., Berghold A., Reisecker F. et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J. Neurol. 2003; 250: 672–675. DOI: 10.1007/s00415-003-1053-9.
20. Sloka J.S., Phillips P.W., Stefanelli M. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J. of Autoimmune Diseases. 2005; 2: 9. DOI:
21. 1186/1740-2557-2-9.
Review
For citations:
Spirin N.N., Kiseleva E.V., Spirina N.N. Analysis of probable predictors of aggressive multiple sclerosis. Bulletin of Siberian Medicine. 2019;18(4):127-135. (In Russ.) https://doi.org/10.20538/1682-0363-2019-4-127-135
Views:
789
Email this article 